Dr. Bilal H. Naqvi
Claim this profileMarshfield Clinic-Minocqua Center
Studies Cancer
Studies Lymphoma
7 reported clinical trials
23 drugs studied
Area of expertise
1Cancer
Stage III
Stage IV
p16 positive
2Lymphoma
CD10 positive
BCL6 positive
CXCL13 positive
Affiliated Hospitals
Clinical Trials Bilal H. Naqvi is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
High-Dose vs Low-Dose Cisplatin with Radiation
for Head and Neck Cancer
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Recruiting1 award Phase 2 & 335 criteria
More about Bilal H. Naqvi
Clinical Trial Related3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Bilal H. Naqvi has experience with
- Cyclophosphamide
- Prednisone
- Cisplatin
- Durvalumab
- Obinutuzumab
- Umbralisib
Breakdown of trials Bilal H. Naqvi has run
Cancer
Lymphoma
Squamous Cell Carcinoma
Oropharyngeal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bilal H. Naqvi specialize in?
Bilal H. Naqvi focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved Stage III patients, or patients who are Stage IV.
Is Bilal H. Naqvi currently recruiting for clinical trials?
Yes, Bilal H. Naqvi is currently recruiting for 2 clinical trials in Minocqua Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Bilal H. Naqvi has studied deeply?
Yes, Bilal H. Naqvi has studied treatments such as Cyclophosphamide, Prednisone, Cisplatin.
What is the best way to schedule an appointment with Bilal H. Naqvi?
Apply for one of the trials that Bilal H. Naqvi is conducting.
What is the office address of Bilal H. Naqvi?
The office of Bilal H. Naqvi is located at: Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin 54548 United States. This is the address for their practice at the Marshfield Clinic-Minocqua Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.